glp-1 liver toxicity Multiple target tissue effects of analogues on non-alcoholic fatty disease (NAFLD) and non-alcoholic steatohepatitis (NASH) Endocrine - Glucagon-like Peptide-1 Receptor-based
Description
Hydration requires deliberate attention
[DOI] [PubMed] [Google Scholar] 68.Zhang X., Zhao Y., Chen S., Shao H
Novo Nordisk also launched an oral tablet form of Wegovy in 2025, making it the first oral GLP-1 approved for weight loss
K.van den BergF
2017;5:e13336
Rules vary by state and federal guidance for controlled substances
